Elutia Inc (ELUT) Fair Value & Analysis
Healthcare · US · Market cap $46.9M
Elutia Inc
ELUT · US
Fair value as of: Jul 16, 2026
From 8 valuation models · updated today
Share price −0.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.5050 – $2.45 · fair‑value band $0.4541 – $1.42 · the $0.9599 price screens above the $0.7999 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Elutia Inc (ELUT) currently trades at $0.9599, while our model-based Fair Value estimate is $0.7999 — implying the stock looks roughly 16.7% overvalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at $12.5M. Revenue declined 48.4% year over year. The balance sheet holds a net cash position of $25.2M. Fundamentals as of Jul 16, 2026
Our scenario range runs from $0.4541 (bear case) to $1.42 (bull case); at $0.9599, the current price sits within that range. The share trades about 64% below its 52-week high and 92% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -45% fair-value upside — at -17%, ELUT screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Elutia Inc reported revenue of $12.3M in FY2025 versus $47.4M in FY2021, a compound −28.6%/yr. Reported net income was $53.4M in FY2025.
Is ELUT fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABL | €73.48 | €59.51 | -19% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDTC34 | R$211.05 | R$29.52 | -86% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| GE HealthCare Technologies Inc GEHC | $63.76 | $44.97 | -29% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥143.50 | ¥111.50 | -22% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Elutia Inc (ELUT) undervalued?
What is the fair value of ELUT?
What is the quality score of ELUT?
What is the revenue of Elutia Inc (ELUT)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Tell me when Elutia Inc reaches its Fair Value
Just your email — and we'll notify you when the price and Fair Value of Elutia Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.